Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.75 |
| ▸ | GABRA1 | P14867 | 8/20 | 0.70 |
| ▸ | GABRG2 | P18507 | 8/20 | 0.70 |
| ▸ | GABRB3 | P28472 | 8/20 | 0.70 |
| ▸ | GABRA3 | P34903 | 8/20 | 0.70 |
| ▸ | GABRA2 | P47869 | 8/20 | 0.70 |
| ▸ | GABRB2 | P47870 | 8/20 | 0.70 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3994500 | 0.87 | POLB (0.77) | POLBLMNAALDH1A1KDM4EGABRA1 | |
| SCHEMBL1558423 | 0.86 | ALDH1A1 (1.00) | POLBLMNAALDH1A1KDM4EGABRA1 | |
| SCHEMBL289605 | 0.85 | POLB (0.74) | POLBLMNAALDH1A1KDM4ERAB9A | |
| SCHEMBL3843612 | 0.83 | POLB (0.71) | POLBLMNAALDH1A1KDM4EGABRA1 | |
| SCHEMBL11681172 | 0.83 | POLB (0.71) | POLBLMNAALDH1A1KDM4EGABRA1 | |
| SCHEMBL11786507 | 0.81 | POLB (0.68) | POLBLMNAALDH1A1KDM4EGABRA1 | |
| SCHEMBL12751524 | 0.80 | POLB (0.67) | POLBLMNAALDH1A1KDM4EGABRA1 | |
| SCHEMBL11771511 | 0.80 | POLB (0.67) | POLBLMNAALDH1A1KDM4EGABRA1 | |
| SCHEMBL13116826 | 0.80 | POLB (0.67) | POLBLMNAALDH1A1KDM4EGABRA1 | |
| SCHEMBL3380253 | 0.80 | POLB (0.67) | POLBLMNAALDH1A1KDM4EGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120276141-A1 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | SRIVASTAVA INDRESH K (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120276141-A1 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | SRIVASTAVA INDRESH K (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120276141-A1 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | SRIVASTAVA INDRESH K (US) | 2012-11-01 | — | — | US | disclosed |
| US-8197819-B2 | Exposure of epitopes on envelop protein; complex of polypeptide and antigen; induce immunology response | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8197819-B2 | Exposure of epitopes on envelop protein; complex of polypeptide and antigen; induce immunology response | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8197819-B2 | Exposure of epitopes on envelop protein; complex of polypeptide and antigen; induce immunology response | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| EP-1773880-A4 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20080199492-A1 | Env Polypeptide Complexes and Methods Of Use | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080199492-A1 | Env Polypeptide Complexes and Methods Of Use | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080199492-A1 | Env Polypeptide Complexes and Methods Of Use | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2008-08-21 | — | — | US | disclosed |
| EP-1773880-A2 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | Novartis Vaccines and Diagnostics, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2005121175-A9 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | CHIRON CORP (US) | 2006-03-16 | — | — | WO | disclosed |
| WO-2005121175-A2 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| US-4110459-A | ANALGESIC | AMERICAN HOECHST CORPORATION (US) | 1978-08-29 | — | — | US | disclosed |
| US-4101663-A | ANTIHYPERTENSIVES | AMERICAN HOECHST CORPORATION (US) | 1978-07-18 | — | — | US | disclosed |
| US-4046900-A | TRANQUILIZERS, HYPOTENSIVES, ANALGESICS | AMERICAN HOECHST CORPORATION (US) | 1977-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080199492-A1 | Env Polypeptide Complexes and Methods Of Use | CD4, CD74, HAVCR2 | POLB 3936/4885LMNA 4015/4885ALDH1A1 4880/4885 |
| US-20120276141-A1 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | CD4, CD74, HAVCR2 | POLB 3936/4885LMNA 4015/4885ALDH1A1 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.